Phaseline

Companies › Huabo Biopharm

Huabo Biopharm: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HB0017 Injection–Phase 2Psoriasis (PsO); PsoriasisDec 2026
HB0025–Phase 1Advanced NSCLC–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06592274HB0017 InjectionPhase 2Psoriasis (PsO)ImmunologyApr 2025
NCT06758557HB0025Phase 1Advanced NSCLCOncologyOct 2025
NCT07920861HB0017 InjectionPhase 1PsoriasisImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Telios Pharma Molecure Tavotek Biotherapeutics Xizang Haisco Pharmaceutical Antengene Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.